<DOC>
	<DOCNO>NCT01119066</DOCNO>
	<brief_summary>The purpose study find effect use system call CliniMACS remove Tcells blood stem cell . Removing T-cells may help stop side effect call Graft-Versus-Host Disease ( GVHD ) . Some study do CliniMACS , Food Drug Administration ( FDA ) yet approve .</brief_summary>
	<brief_title>HLA-Compatible Related Unrelated Donors With CD34+ Enriched , T-cell Depleted Peripheral Blood Stem Cells Isolated CliniMACS System Treatment Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Malignant condition life threaten disorder correctable transplant CD34+ select , Tcell deplete allogeneic hematopoietic stem cell transplantation indicate : AML 1st remission patient whose AML 'good risk ' cytogenetic feature ( i.e . 8 ; 21 , t15 ; 17 , inv 16 ) . Secondary AML 1st remission AML 1st relapse &gt; = 2nd remission ALL/CLL 1st remission clinical molecular feature indicate high risk relapse ; ALL/CLL &gt; = 2nd remission CML fail respond tolerate Imatinib dasatinib first chronic phase disease ; CML accelerate phase second chronic phase CR accelerate phase blast crisis . NonHodgkins lymphoma chemoresponsive disease follow category : 1. intermediate high grade lymphoma fail achieve first CR relapse follow 1st remission candidate autologous transplant . 2. NHL remission consider curable chemotherapy alone eligible/appropriate autologous transplant . Myelodysplastic syndrome ( MDS ) : RA//RARS/RCMD high risk cytogenetic feature transfusion dependence well RAEB1 RAEB2 Acute myelogenous leukemia ( AML ) evolve MDS , eligible transplantation and/or unable enroll onto protocol IRB 08008 . Chronic myelomonocytic leukemia : CMML1 CMML2 . Multiple Myeloma disease follow category : 1 . Patients relapse multiple myeloma follow autologous stem cell transplantation achieve least partial response follow additional chemotherapy . 2 . Patients high risk cytogenetics diagnosis must achieve partial response follow autologous stem cell transplantation . Patients must complex karyotype , del17p , t4 ; 14 and/or t14 ; 16 FISH and/or del13 karyotyping . Other rare lethal disorder Hematopoiesis Lymphopoiesis Tcell deplete transplant indicate ( e.g . hemophagocytic lymphohistiocytosis ; refractory aplastic anemia congenital cytopenia ; nonSCID lethal genetic immunodeficiency Wiskott Aldrich Syndrome , CD40 ligand deficiency , ALPS , well refractory autoimmune cytopenia , PNH , metabolic storage disease heavily transfuse congenital hemoglobinopathy ) . Accrual treatment arm include 30 standard risk 30 poor risk patient ( 60 patients/treatment arm ) except Regimen D , include 30 patients/treatment arm , poor risk virtue risk relapse and/or transplant relate mortality . Standard risk patient include eligible patient , define , receive transplant treatment MDS RA//RARS/RCMD , AML 1st 2nd remission , ALL 1st CR , NHL 1st remission , MM 1st remission , Very Good Partial Response , 1st Partial Response CML first chronic phase 1st remission . All patient , include treatment related malignancy and/or AML derive MDS , receive extensive prior chemo/radiotherapy , therefore , consider poor risk condition transplant related morbidity , potentially transplant related mortality . Patients life threaten nonmalignant genetic acquire disorder also , virtue history , optional transfusion and/or infection consider poor risk . Stopping rule nonrelapse relate mortality heavily treat patient , therefore , slightly less stringent patient poor risk transplant group . Stopping rule principal endpoint graft failure GvHD group . The following inclusion criterion also require : Patient 's age include birth &lt; 70 year old . Patients may either gender ethnic background . Patients must Karnofsky ( adult ) Lansky ( pediatric ) Performance Status &gt; = 70 % Patients must adequate organ function measure : Cardiac : asymptomatic symptomatic LVEF rest must &gt; = 50 % must improve exercise . Hepatic : &lt; 3x ULN AST â‰¤ 1.5 total serum bilirubin , unless congenital benign hyperbilirubinemia hyperbilirubinemia directly cause disease patient receive transplant ( e.g . AML Chloroma obstruct biliary tree ) . Patients high bilirubin level due cause active liver disease also eligible PI approval e.g . patient PNH , Gilbert 's disease hemolytic disorder . Renal : serum creatinine &lt; = 1.2 mg/dl serum creatinine outside normal range , CrCl &gt; 40 ml/min ( measure calculated/estimated ) Pulmonary : asymptomatic symptomatic , DLCO &gt; = 50 % predict ( correct hemoglobin ) Each patient must willing participate research subject must sign informed consent form . Female patient pregnant breastfeed Active viral , bacterial fungal infection Patient seropositive HIVI/II ; HTLV I/II Presence leukemia CNS . Donor Each donor must meet criterion outline institutional guideline Donor agree undergo general anesthesia bone marrow harvest collection PBSC yield inadequate otherwise transplantable whatever reason . Donor Exclusion Criteria If donor meet institutional guideline , exclusion consider .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>radiation</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>fludarabine</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>CliniMACS device</keyword>
	<keyword>GCSF</keyword>
	<keyword>10-050</keyword>
</DOC>